Ubs Group Ag Neoleukin Therapeutics, Inc. Transaction History

Ubs Group Ag

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$0.68 - $0.91 $9,387 - $12,562	-13,805 Reduced 92.62%	1,100 $0
Q1 2023 May 12, 2023	SELL	$0.5 - $0.72 $3,442 - $4,956	-6,884 Reduced 31.59%	14,905 $10,000
Q4 2022 Feb 08, 2023	BUY	$0.4 - $0.55 $2,915 - $4,008	7,289 Added 50.27%	21,789 $11,000
Q3 2022 Nov 10, 2022	BUY	$0.69 - $1.33 $9,246 - $17,822	13,400 Added 1218.18%	14,500 $10,000
Q1 2022 May 16, 2022	SELL	$1.72 - $5.23 $21,040 - $63,978	-12,233 Reduced 91.75%	1,100 $2,000
Q4 2021 Feb 14, 2022	BUY	$4.65 - $7.75 $42,742 - $71,238	9,192 Added 221.98%	13,333 $64,000
Q3 2021 Nov 15, 2021	BUY	$6.05 - $9.66 $423 - $676	70 Added 1.72%	4,141 $30,000
Q2 2021 Aug 13, 2021	SELL	$9.23 - $13.12 $305,780 - $434,652	-33,129 Reduced 89.06%	4,071 $38,000
Q1 2021 May 12, 2021	BUY	$11.26 - $15.78 $394,145 - $552,363	35,004 Added 1593.99%	37,200 $458,000
Q4 2020 Feb 11, 2021	SELL	$10.17 - $14.56 $33,245 - $47,596	-3,269 Reduced 59.82%	2,196 $31,000
Q3 2020 Nov 12, 2020	SELL	$9.68 - $17.01 $86,277 - $151,610	-8,913 Reduced 61.99%	5,465 $66,000
Q2 2020 Jul 31, 2020	BUY	$9.95 - $17.05 $78,525 - $134,558	7,892 Added 121.68%	14,378 $238,000
Q1 2020 May 01, 2020	BUY	$6.12 - $13.64 $15,214 - $33,909	2,486 Added 62.15%	6,486 $74,000
Q4 2019 Feb 14, 2020	SELL	$2.65 - $12.72 $2,811 - $13,495	-1,061 Reduced 20.96%	4,000 $49,000
Q3 2019 Nov 14, 2019	BUY	$2.33 - $3.76 $11,792 - $19,029	5,061 New	5,061 $14,000

199K

Ticker NLTX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 42,579,900
Description
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of vario...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.